Serious adverse events Adverse events · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in serious adverse events Adverse events compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).
1 finding from 1 review
Serious adverse events (n/N)
Summary of findings: insulin glargine showed no clear difference in serious adverse events (n/N) compared with NPH insulin (moderate certainty).
1 finding from 1 review
Serious adverse events (n/N)
Summary of findings: insulin detemir showed no clear difference in serious adverse events (n/N) compared with insulin glargine (low certainty).
1 finding from 1 review
Serious adverse events (n/N)
Summary of findings: insulin degludec showed no clear difference in serious adverse events (n/N) compared with insulin detemir (low certainty).
1 finding from 1 review
Serious adverse events (n/N)
Summary of findings: insulin degludec showed no clear difference in serious adverse events (n/N) compared with insulin glargine (low certainty).
1 finding from 1 review
Serious adverse events (n/N)
Summary of findings: insulin detemir showed no clear difference in serious adverse events (n/N) compared with NPH insulin (moderate certainty).
1 finding from 1 review
Serious adverse events (during · children or adults with Types I or II HAE
Berotralstat showed no clear difference in serious adverse events (during compared with placebo or active control (low certainty).
1 finding from 1 review
Serious adverse events (during · children or adults with Types I or II HAE
It is very uncertain whether C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
1 finding from 1 review
Serious adverse events (during · children or adults with Types I or II HAE
It is very uncertain whether plasma‐derived C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
1 finding from 1 review
Serious adverse events (during · children or adults with Types I or II HAE
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (during · children or adults with Types I or II HAE
It is very uncertain whether recombinant human C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
1 finding from 1 review
Serious adverse events (during · children or adults with Types I or II HAE
It is very uncertain whether avoralstat changes serious adverse events (during compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events (during · children or adults with Types I or II HAE
Lanadelumab showed no clear difference in serious adverse events (during compared with placebo or active control (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events 49 weeks · adults with asthma
The intervention showed no clear difference in serious adverse events 49 weeks (low certainty).
1 finding from 1 review
Serious adverse events 17 weeks · adults with asthma well controlled on LABA and ICS
Stopping LABA showed no clear difference in serious adverse events 17 weeks compared with continuing use of LABA+ICS (moderate certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in non‐fatal serious adverse events compared with formoterol (moderate certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in non‐fatal serious adverse events compared with aclidinium alone (moderate certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Tiotropium + LABA/ICS combination showed no clear difference in serious adverse events (non‐fatal) compared with tiotropium (low certainty).
1 finding from 1 review
Serious adverse events (3‐week to 1‐year · Adults with COPD
Once‐daily LABA/LAMA in a combined inhaler showed no clear difference in serious adverse events (3‐week to 1‐year compared with placebo (high certainty).
1 finding from 1 review